Pattern Of Use And Safety/Effectiveness Of Nivolumab In Routine Oncology Practice
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active
The Study's objectives are to estimate the incidence rates and severity of immune related and severe infusion reactions in patients treated with nivolumab for melanoma, lung cancer, and in routine oncology practice.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.